30 closest matches · ranked by relevance
Mucinous Adenocarcinoma of the Colon · Mucinous Adenocarcinoma of the Rectum · Signet Ring Adenocarcinoma of the Colon
Primary: Proportion of Patients Alive and Progression-free at 15 Months — .482 proportion of participants
Colorectal Neoplasms
Primary: Percentage of Patients With Treatment-Emergent Adverse Events (TEAEs) in the Specified Categories Selected for Primary Endpoint Assessment — 58.5; 18.7; 12.2; 2.4…
Neoplasm Metastasis · Colorectal Cancer
Primary: Best Overall Response Rate - Independent Review Committee (IRC) — 45.6; 35.7 percentage of participants — p=0.064
Metastatic Colorectal Cancer
Primary: Objective Response Rate — 56.47; 37.93 percentage of participants
Colorectal Cancer · Neoplasm Metastasis
Primary: Response Rate for the Combination Treatment — 21 Participants
Colorectal Cancer
Primary: Percentage of Participants Achieving Complete Resection (R0 Resection) — 30.0 percentage of participants
Colorectal Cancer
Primary: Progression Free Survival — 9.9; 10.3 Months
Colorectal Cancer
Primary: Overall Response Rate (ORR) — 75 percentage of evaluable participants
Colorectal Cancer Metastatic
Primary: Sorafenib Activity — 123 days
Metastatic Colorectal Cancer
Primary: Overall Survival — 196; 151 Days — p=0.005178
Metastatic Colorectal Cancer
Primary: Progression-free Survival — 8.6; 8.2 Months
Advanced Colorectal Cancer
Primary: Progression-free Survival Rate at Three Months — 20.7 percentage of participants
Colorectal Carcinoma
Primary: Progression-Free Survival Rate (PFS Rate) at 9 Months After Randomization — 46.4; 47.4 percentage of participants
Colorectal Neoplasms · Neoplasm Metastasis
Primary: Overall Survival (OS) — 12.06; 13.50 months — p=0.0032
Colorectal Cancer
Primary: Percentage of Participants in Objective Response (Partial or Complete Responses) — 47.5 percentage of participants
Colorectal Cancer
Primary: Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor — 48.7; 61.0; 33.3; 51.2 percentage of participants — p=0.2707
Colon Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 55 percentage of patients
Colorectal Neoplasms
Primary: Objective Response (OR) — 0.4390 Proportion of participants — p=0.36
Colorectal Cancer Metastatic
Primary: Progression Free Survival (PFS) — 6.1; 5.3 Months
BRAF V600E-mutant Metastatic Colorectal Cancer
Primary: Confirmed Overall Response Rate (cORR) Based on Local Tumor Assessments — 47.8 percentage of confirmed responses
Colorectal Neoplasms · Neoplasm Metastasis
Primary: Progression Free Survival (PFS) Rate at 12 Months — 21.2; 25.8 percentage of participants
Metastatic Colorectal Cancer
Primary: Progression-Free Survival (PFS) — 11.0; 8.3 months
Colorectal Cancer
Primary: Progression-free Survival (PFS) as Assessed by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) by General Approach (Participants With…
Colorectal Cancer Metastatic
Primary: Progression-free Survival (PFS) — 5.59; 6.93 months
Colorectal Cancer
Primary: Progression Free Survival (PFS) — 4.731; 0.986 months
Metastatic Colorectal Cancer
Primary: Rate of Patients Alive and Progression-free 6 Months After Inclusion. — 22 Nb of patients alive without progression
Colorectal Cancer
Primary: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 — 10.09; 12.55 months — p=0.0555
Colorectal Neoplasms
Primary: Percentage of Participants With Objective Response — 3; 20 Percentage of Participants — p=0.0735
Colorectal Cancer Metastatic
Primary: Dose-limiting-toxicities (DLTs) (Phase 1) — 0; 0; 0; 0 Participants
Colorectal Cancer
Primary: Overall Survival (OS) — 13.3; 11.7 months — p=0.0219